Sanofi CEO Paul Hudson: AI will improve efficiency and change the cost and speed of drug development

Watch on YouTube ↗  |  January 22, 2026 at 14:14  |  8:21  |  CNBC
Speakers
Paul Hudson — CEO, Sanofi

Summary

Sanofi CEO Paul Hudson joins Squawk Box to discuss the pharmaceutical landscape, U.S.-Europe drug pricing, TrumpRx discounts, Sanofi's pipeline, rare disease franchise, and AI in drug development. Hudson is optimistic on Sanofi's commercial momentum, top-line growth, pipeline readouts, and resilience to pricing pressure. He highlights Sanofi's leadership in rare diseases and early adoption of AI to improve R&D efficiency.

  • Paul Hudson, Sanofi CEO, discusses drug pricing and policy.
  • Sanofi sees Q3 commercial performance outstanding and targets top-decile growth.
  • Pipeline readouts expected over next 12-24 months.
  • Innovation is viewed as key to navigating pricing pressure.
  • Sanofi is a leading rare disease player with successful launches.
  • AI is being used in R&D governance to improve efficiency and speed.
  • Drug pricing debate outcome remains uncertain.
  • Hudson remains optimistic on Sanofi's positioning.
Ideas
Paul Hudson CEO, Sanofi 2:43
Sanofi uses AI for R&D efficiency.
Hudson argues Sanofi is positioned for top-decile top-line growth after the obesity companies, with Q3 commercial performance outstanding and a late-stage pipeline approaching readouts over the next 12 to 24 months. He says innovation and improved business execution/resource allocation will protect Sanofi despite U.S.-Europe drug-pricing pressure.
SNY HIGH
Paul Hudson CEO, Sanofi 2:53
Innovation is what pharma rewards.
Hudson argues innovation is the only thing that will be rewarded in pharma when all is said and done. Companies doing first-in-class/best-in-class drugs, researching rare diseases and unmet needs, will be what health systems pay for, and innovation should become more prominent as the political narrative changes.
XPH HIGH
Paul Hudson CEO, Sanofi 7:12
AI improves pharma drug development.
Hudson says AI will improve efficiency and change the cost and speed of drug development, benefiting the pharmaceutical industry broadly. He expects regulatory and process timelines to improve as AI is adopted.
AI-SECTOR HIGH
Up Next
14:53
Lutnick Says Relations With Europe, Greenland Are Fine
Bloomberg Markets · Jan 22
8:00
Wells Fargo CEO Charlie Scharf on state of the economy, credit card rate cap and company outlook
CNBC · Jan 22
7:09
Liberty Global CEO Mike Fries on U.S.-Europe relations, state of telecom and AI impact
CNBC · Jan 22
1:59
Davos: Nigel Farage Wants to Challenge UK's Entire Economic Policy
Bloomberg Markets · Jan 22
8:12
Sierra CEO Bret Taylor on the future of AI: We're at the beginning of the curve
CNBC · Jan 22

This CNBC video, published January 22, 2026, features Paul Hudson discussing SNY, XPH, AI-SECTOR. 3 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Paul Hudson  · Tickers: SNY, XPH, AI-SECTOR